Authors
Latest:
Later-Generation Cell Therapies Increase Utility in Hematologic MalignanciesCAR T-cell therapy use will likely expand to a wider array of hematologic malignancies.
Latest:
Jay Spiegel, MD, FRCPC, on 5-Year Real-World Outcomes From Axi-cel in R/R LBCLThe hematologist and cell therapist from the University of Miami Sylvester Comprehensive Cancer Center spoke about long-term outcome data he presented at ASH’s 2023 conference.
Latest:
Veit Bücklein, Dr Med, on Research Trends in Hematological Malignancy Cell TherapyThe postdoctoral researcher at Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, discussed research he was excited to see at ASH 2023 and in the field in general.
Latest:
Targeting Progranulin With Gene Therapy for Frontotemporal DementiaWilliam Chou, MD, president and chief executive officer of Passage Bio, discussed feedback from a recent Type C meeting with the FDA.
Latest:
Samir Parekh, MD, on Surprising Efficacy of Sequential T-Cell Redirection Therapy in Multiple MyelomaThe director of translational research in myeloma at the Tisch Cancer Institute discussed the relevance of the new research as more CAR T therapies come to market.
Latest:
Jay Barth, MD, on Ascidian Therapeutics' Developments in Gene TherapyCGTLive's sister publication spoke with Barth, the chief medical officer at Ascidian, about the company’s attempts to develop a new method of administration for gene therapy at ARVO 2023.
Latest:
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and AccessibilityThe pediatric neurologist at Nemours Children’s Health discussed next steps in the field to fully enable the benefits of gene therapy.
Latest:
Sung-Yun Pai, MD, on Further Research With Lentiviral Gene Therapy for X-SCIDThe senior investigator at the National Cancer Institute Center for Cancer Research discussed unmet needs that remain and further research to be done.
Latest:
Evan Mizerak, on Developing an ASO Targeting CAPN2 for ALSThe lead of preclinical research at Amylyx Pharmaceuticals discussed the literature supporting AMX0114’s target and its upcoming trial design.
Latest:
Payer Challenges for Patient Access to Autologous Cell and Gene TherapiesAutologous cell and gene therapies show promise but face barriers such as high costs, limited access, and payer concerns over long-term effectiveness.
Latest:
Allogeneic Stem Cell Transplant for Acute Myeloid LeukemiaThe hematologist from UC Health discussed the role of allogeneic stem cell transplant at first remission based on risk stratification.
Latest:
Alba Gonzalez-Junca, PhD, on Logic-gated CAR-NK Cell DevelopmentThe associate director of Research at Senti Biosciences discussed the company's research on using logic-gated CAR-NK cells for the treatment of AML and solid tumors.
Latest:
Aliya Rashid, DO, MPH, on Further Research With Gender Inequality in CAR T Paper AuthorshipThe internal medicine resident physician at University of Kansas Medical Center also discussed highlights from the ASH 2023 meeting.
Latest:
Matthew B. Harms, MD, on the Necessity of Tracking Gene Mutations in ALSThe associate professor of neurology at Columbia University spoke about the importance of identifying patients with ALS-associated gene mutations as early as possible.
Latest:
Dr. Usmani on the Potential Utility of Allogeneic CAR T-Cell Therapy in Multiple MyelomaSaad Z. Usmani, MD, FACP, discusses the potential utility of allogeneic CAR T-cell therapy in multiple myeloma.
Latest:
Julie Kanter, MD, on Highest Priorities for Sickle Cell After Gene Therapy ApprovalsThe director of the Adult Sickle Cell Clinic and associate professor at University of Alabama Birmingham pointed out access to a sickle cell specialist as one such priority.
Latest:
Levi Gray-Rupp, PhD, on Using Integrated Circuit T-Cells Against Solid TumorsThe senior director of immunology at Arsenal Bio discussed advantages of ICTs and the company’s clinical trial in ovarian cancer.
Latest:
Mantle Cell Lymphoma Outcomes May Improve With Bispecific CD20/CD19-targeted CAR T-cell TherapiesNirav N. Shah, MD, associate professor at the Medical College of Wisconsin in Milwaukee, discussed the evaluation of LV20.19 CAR in MCL, as well as key efficacy and safety data on the therapy to date.
Latest:
Thomas Martin, MD, on Exciting Cell Therapy Options in Multiple MyelomaThe clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed cilta-cel and upcoming cell therapies.
Latest:
Slowing Tumor Growth in Glioblastoma With Novel AAV TherapyLisa Nieland, a PhD candidate from Lieden University Medical Center and Breakefield Lab at Mass Gen, discussed her work presented at the ASGCT 2024 meeting.
Latest:
Stacy Lindborg, PhD, on Addressing Unmet Needs in ALS With Cell TherapyThe co-CEO of BrainStorm Cell Therapeutics spoke about the current standards of care in ALS and the potential of NurOwn to address unmet needs.
Latest:
Early Signals of Efficacy With Cystic Fibrosis Gene TherapyJennifer L. Taylor-Cousar, MD, MSCS, a professor of internal medicine and pediatrics at National Jewish Health discussed updated data from the phase 1/2 AEROW trial of 4D-710.
Latest:
Maria Escolar, MD, on the Importance of Newborn Screening for Treating Krabbe DiseaseThe chief medical officer of Forge Biologics discussed how expanded newborn screening practices may help the company’s gene therapy for Krabbe disease, FBX-101, reach more patients.
Latest:
Christian Hinrichs, MD, on Improving Solid Tumor Targeting With Engineered T-Cell TherapiesThe chief of cancer immunotherapy at Rutgers Cancer Institute discussed clinical results with different cell therapy approaches.
Latest:
Gene Therapy for GM1 Gangliosidosis: Latest UpdatesRalph Laufer, PhD, chief scientific officer, Lysogene, discussed gene therapy programs in GM1 gangliosidosis and Fragile X syndrome.
Latest:
Pietro Genovese, PhD, on Using Base-Editing to Protect Healthy Stem Cells from Immunotherapy ToxicityThe principal investigator at the Gene Therapy Program of Dana-Farber/Boston Children’s Cancer and Blood Disorder Center discussed innovative uses of gene editing technology.
Latest:
Alexis Thompson, MD, MPH, on the Simultaneous Approvals of Exa-cel and Lovo-cel For SCDThe chief of hematology at Children’s Hospital of Philadelphia discussed dual approval of the 2 gene therapies that coincided with ASH’s 2023 conference.
Latest:
Samiah Al-Zaidy, MD, on Gene Therapy for Infantile GM1 GangliosidosisAl-Zaidy, the vice president of clinical development and lead on the GM1 Program at Passage Bio, discussed the results of the phase 1/2 Imagine-01 clinical trial of PBGM01.
Latest:
Promising Outlook in Multiple Myeloma with Cilta-Cel: Philippe Moreau, MDPhilippe Moreau, MD, discussed the CARTITUDE-1 trial's promising results with ciltacabtagene autoleucel read out at the 2021 ASCO Annual Meeting.
